Gilead SciencesFRA:GIS +0.78%75 Current Ratio is 1.97 as of Mar. 2026, which is 25% above its 10-year median of 1.58. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, Gilead Sciences ranks worse than 50.6% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Gilead Sciences's current ratio for the quarter that ended in Mar. 2026 was 1.97.
Gilead Sciences has a current ratio of 1.97. It generally indicates good short-term financial strength.
The historical rank and industry rank for Gilead Sciences's Current Ratio or its related term are showing as below:
FRA:GIS'
s Current Ratio Range Over the Past 10 Years
Min: 1.02 Med: 1.58 Max: 3.76
Current: 1.97
During the past 13 years, Gilead Sciences's highest Current Ratio was 3.76. The lowest was 1.02. And the median was 1.58.
FRA:GIS's Current Ratio is ranked worse than 50.6% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:GIS: 1.97
Gilead Sciences (FRA:GIS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Gilead Sciences Current Ratio Related Terms
Gilead Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, AMGN, BMY: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Current Ratio of 1.97 as of Mar. 2026. This is 25% above median its historical median of 1.58. Over the past decade, Gilead Sciences' Current Ratio has ranged from 1.02 to 3.76. According to the industry distribution chart, Gilead Sciences ranks #504 out of 996 companies in the Drug Manufacturers industry, placing it in the top 50.6%.
Is Gilead Sciences' Current Ratio too high?
Gilead Sciences' current Current Ratio of 1.97 is 25% above median its 10-year median of 1.58. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 3.76. The Drug Manufacturers industry median Current Ratio is 2.00. Gilead Sciences' value of 1.97 is 1.5% below this industry median. Based on the distribution chart, Gilead Sciences ranks #504 out of 996 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Current Ratio compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #504 out of 996 companies for Current Ratio. This places Gilead Sciences in the lower half of its industry. The industry median Current Ratio is 2.00. Gilead Sciences' value of 1.97 is 1.5% below this benchmark. Historically, Gilead Sciences' own Current Ratio has ranged from 1.02 to 3.76 over the past decade. While the company's 10-year median is 1.58 vs. the industry median of 2.00, Gilead Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Current Ratio of 1.97 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Current Ratio is 1.97, which is 25% above median its own 10-year median of 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.31, compared to a current price of €110.86 — trading 34.7% above its estimated fair value. The current Current Ratio is 1.97, which is 25% above median its 10-year median of 1.58 and 1.5% below the Drug Manufacturers industry median of 2.00. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Current Ratio is 1.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €110.86 is trading 34.7% above its estimated GF Value™ of €82.31.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Current Ratio: 1.97 (25% above median its 10-year median of 1.58)
GF Value™: €82.31 vs. price of €110.86 (34.7% above fair value)
Industry Position: 1.5% below the Drug Manufacturers median (#504 of 996)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
